Cagrilintide (5mg/10mg)

What is Cagrilintide?

A novel long-acting amylin analog (Novo Nordisk) being studied with semaglutide as 'CagriSema' — one of the most anticipated next-generation obesity peptides.

Listed vial contents: 5mg / 10mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Cagrilintide is a long-acting amylin analog engineered with a C18 fatty diacid for albumin binding, extending half-life to approximately 7 days for once-weekly dosing. It activates calcitonin and amylin (AMY1, AMY2, AMY3) receptors, slowing gastric emptying and reducing food intake through a satiety pathway that is independent of, and additive to, GLP-1 signaling.

What are the research questions?

• Weight management: Studied alone and in fixed-ratio combination with semaglutide ('CagriSema'). REDEFINE-1 (NEJM 2025) reported 20.4% mean body weight reduction with CagriSema at 68 weeks.
• Type 2 diabetes: REDEFINE-2 trial evaluating CagriSema for glycemic control alongside weight reduction.
• Complementary metabolic pathway: Investigated specifically because amylin/GLP-1 dual targeting recruits two distinct satiety circuits.

What does the published work describe?

REDEFINE-1 (2025): 20.4% weight reduction with CagriSema vs 14.9% semaglutide and 11.5% cagrilintide alone. Tolerability profile similar to semaglutide, with predominantly mild-to-moderate GI events.

What are the limits of this evidence?

The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.

Study references

1. Enebo LB et al. Lancet 2021;397:1736-1748 — Phase 1b cagrilintide+sema
2. Garvey WT et al. NEJM 2025 — REDEFINE-1

These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Cagrilintide handled in the lab?

Plan a Cagrilintide stock solution from the sequence, the listed molecular weight (3789.43 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave